Literature DB >> 23535881

Mixed bloodstream infections involving bacteria and Candida spp.

Emilio Bouza1, Almudena Burillo, Patricia Muñoz, Jesús Guinea, Mercedes Marín, Marta Rodríguez-Créixems.   

Abstract

OBJECTIVES: Polymicrobial bloodstream infection (BSI) is an imprecisely defined entity purportedly associated with a worse outcome than monomicrobial BSI. This study examines trends in BSI episodes caused by bacteria and Candida spp. (mixed-BSI) in a large teaching hospital.
METHODS: All episodes of BSI from January 2000 to December 2010 were reviewed. Three groups (n = 54 each) of patients were compared: all adults with mixed-BSI from January 2006 to December 2010 (cases) and randomly selected patients with polybacterial BSI (polyB-BSI) (Control 1) or Candida spp. BSI (Candida-BSI) (Control 2) in this same period.
RESULTS: A total of 139 episodes of mixed-BSI were recorded (0.7% of all BSI, 6.9% of all poly-BSI and 18.0% of all Candida-BSI episodes). The incidence of mixed-BSI was 0.21 cases/1000 admissions, increasing from 0.08 (2000) to 0.34 (2010) cases/1000 admissions (P = 0.007). Mixed-BSI represented 11.8% and 22.9% of all episodes of candidaemia in 2000 and 2010, respectively (P = 0.011). Compared with polyB-BSI, mixed-BSI patients showed fewer malignancies, more frequent nosocomial or intravenous catheter BSI source and less frequent intra-abdominal origin, were more frequently admitted to an intensive care unit (ICU), received more antimicrobials and showed a longer hospital stay and higher mortality. Compared with Candida-BSI, mixed-BSI patients showed more severe underlying diseases, were more frequently admitted to an ICU or oncology-haematology unit, showed a higher APACHE II score, more often progressed to septic shock or multiorgan failure and received more antimicrobials. Mortality was similar.
CONCLUSIONS: Mixed-BSI is a rare, distinct infection with a worse prognosis than polyB-BSI. We were unable to detect differences in the prognosis of mixed-BSI when compared with Candida-BSI.

Entities:  

Keywords:  bacteraemia; candidaemia; coinfection; polymicrobial bacteraemia; polymicrobial candidaemia

Mesh:

Year:  2013        PMID: 23535881     DOI: 10.1093/jac/dkt099

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  Evaluation of the Bruker® MBT Sepsityper IVD module for the identification of polymicrobial blood cultures with MALDI-TOF MS.

Authors:  Anaïs Scohy; Audrey Noël; Anca Boeras; Laetitia Brassinne; Terry Laurent; Hector Rodriguez-Villalobos; Alexia Verroken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-20       Impact factor: 3.267

2.  Inhibition of nucleic acid biosynthesis makes little difference to formation of amphotericin B-tolerant persisters in Candida albicans biofilm.

Authors:  Jing Sun; Xiaohua Liu; Guangshui Jiang; Qingguo Qi
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

3.  Candidemia in patients with head and neck cancer: mortality and a novel risk factor.

Authors:  Kensuke Uraguchi; Takuma Makino; Shin Kariya; Youhei Noda; Hidenori Marunaka; Akira Doi; Kenichi Kozakura; Soshi Takao; Mizuo Ando
Journal:  Support Care Cancer       Date:  2022-04-06       Impact factor: 3.603

Review 4.  Clinical and microbiological characteristics of polymicrobial bacteremia: a retrospective, multicenter study.

Authors:  Shinnosuke Fukushima; Hideharu Hagiya; Koji Fujita; Shinya Kamiyama; Haruto Yamada; Masayuki Kishida; Fumio Otsuka
Journal:  Infection       Date:  2022-03-17       Impact factor: 7.455

5.  Candida albicans Amphotericin B-Tolerant Persister Formation is Closely Related to Surface Adhesion.

Authors:  Jing Sun; Zhigang Li; Haoyue Chu; Jing Guo; Guangshui Jiang; Qingguo Qi
Journal:  Mycopathologia       Date:  2015-09-18       Impact factor: 2.574

6.  Composite PLGA/AgNpPGA/AscH nanospheres with combined osteoinductive, antioxidative, and antimicrobial activities.

Authors:  Magdalena Stevanović; Vuk Uskoković; Miloš Filipović; Srečo D Škapin; Dragan Uskoković
Journal:  ACS Appl Mater Interfaces       Date:  2013-09-09       Impact factor: 9.229

7.  Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix.

Authors:  Eric F Kong; Christina Tsui; Sona Kucharíková; David Andes; Patrick Van Dijck; Mary Ann Jabra-Rizk
Journal:  MBio       Date:  2016-10-11       Impact factor: 7.867

Review 8.  Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?

Authors:  Vasiliki Soulountsi; Theodoros Schizodimos; Serafeim Chrysovalantis Kotoulas
Journal:  Infection       Date:  2021-06-16       Impact factor: 3.553

9.  Novel dental implant modifications with two-staged double benefits for preventing infection and promoting osseointegration in vivo and in vitro.

Authors:  Xiaoyu Huang; Yang Ge; Bina Yang; Qi Han; Wen Zhou; Jingou Liang; Mingyun Li; Xian Peng; Biao Ren; Bangcheng Yang; Michael D Weir; Qiang Guo; Haohao Wang; Xinxuan Zhou; Xugang Lu; Thomas W Oates; Hockin H K Xu; Dongmei Deng; Xuedong Zhou; Lei Cheng
Journal:  Bioact Mater       Date:  2021-05-15

Review 10.  Recent insights into Candida albicans biofilm resistance mechanisms.

Authors:  Lotte Mathé; Patrick Van Dijck
Journal:  Curr Genet       Date:  2013-08-25       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.